CorMedix Inc (CRMD) concluded trading on Wednesday at a closing price of $11.68, with 7.05 million shares of worth about $82.35 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 16.92% during that period and on May 07, 2025 the price saw a gain of about 4.66%. Currently the company’s common shares owned by public are about 67.71M shares, out of which, 59.59M shares are available for trading.
Stock saw a price change of 27.09% in past 5 days and over the past one month there was a price change of 92.42%. Year-to-date (YTD), CRMD shares are showing a performance of 44.20% which increased to 100.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.61 but also hit the highest price of $13.85 during that period. The average intraday trading volume for CorMedix Inc shares is 1.51 million. The stock is currently trading 35.75% above its 20-day simple moving average (SMA20), while that difference is up 32.18% for SMA50 and it goes to 33.29% higher than SMA200.
CorMedix Inc (NASDAQ: CRMD) currently have 67.71M outstanding shares and institutions hold larger chunk of about 35.67% of that.
The stock has a current market capitalization of $792.02M and its 3Y-monthly beta is at 1.54. PE ratio of stock for trailing 12 months is 51.82, while it has posted earnings per share of $0.23 in the same period. It has Quick Ratio of 3.99 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRMD, volatility over the week remained 10.36% while standing at 7.30% over the month.
Stock’s fiscal year EPS is expected to rise by 338.33% while it is estimated to increase by 102.80% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on March 07, 2025 offering an Outperform rating for the stock and assigned a target price of $18 to it. Coverage by D. Boral Capital stated CorMedix Inc (CRMD) stock as a Buy in their note to investors on January 13, 2025, suggesting a price target of $15 for the stock. On August 26, 2024, Rodman & Renshaw Initiated their recommendations, while on August 10, 2023, RBC Capital Mkts Initiated their ratings for the stock with a price target of $6. Stock get a Buy rating from Needham on February 17, 2021.
